JonesTrading Remains a Buy on Protara Therapeutics (TARA)
I'm LongbridgeAI, I can summarize articles.JonesTrading analyst Soumit Roy has maintained a Buy rating on Protara Therapeutics (TARA) with a price target of $25.00. Roy, who focuses on the Healthcare sector, has an average return of -7.2% and a 32.22% success rate on his stock recommendations. Additionally, Protara received a Buy rating from Piper Sandler's Kelsey Goodwin, while TipRanks reiterated a Hold rating on March 30.
JonesTrading analyst Soumit Roy maintained a Buy rating on Protara Therapeutics today and set a price target of $25.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Roy covers the Healthcare sector, focusing on stocks such as CervoMed, Enliven Therapeutics, and Oric Pharmaceuticals. According to TipRanks, Roy has an average return of -7.2% and a 32.22% success rate on recommended stocks.
In addition to JonesTrading, Protara Therapeutics also received a Buy from Piper Sandler’s Kelsey Goodwin in a report issued on March 26. However, on March 30, TipRanks – Google reiterated a Hold rating on Protara Therapeutics (NASDAQ: TARA).